Merck KGaA. (1/28/19). "Press Release: Boards of E. Merck KG Newly Elected. Incumbent Chairmen Re-elected". Darmstadt.

	Organisation	Merck KGaA
	Group	Merck (DE) (Group)
	Product	CHEMICALS
	Product 2	pharmaceutical
	Person	Stangenberg-Haverkamp, Frank (Merck (DE) 201401– Chairman of Family Board of E Merck)
	Person 2	Baillou, Johannes (Merck (DE) 201401– Chairman of Board of Partners E Merck KG)

At the Partners’ Meeting of E. Merck KG (EM), last weekend the Merck family partners elected their representatives to the Family Board and Board of Partners in a regularly scheduled election held every five years. The incumbent chairmen of these two boards were re-elected:

> Dr. Frank Stangenberg-Haverkamp (70), Chairman of the Family Board of E. Merck KG since 2014 (simultaneously Deputy Chairman of the Board of Partners; Chairman of the Executive Board and personally liable partner of EM) and

> Johannes Baillou (53), Chairman of the Board of Partners of E. Merck KG since 2014 (simultaneously Deputy Chairman of both the Family Board and the Executive Board and personally liable partner of EM).

The nine-member Board of Partners was elected by the Family Board. Among others, two external members were re-elected and two external members were newly elected. The latter are:

> Michael Kleinemeier (61), Member of the Executive Board of SAP SE responsible for the Digital Business Services organization and

> Helene von Roeder (48), Member of the Management Board and CFO of Vonovia SE.

Together with Dr. Frank Stangenberg-Haverkamp and Johannes Baillou mentioned previously, as well as Dr. Wolfgang Büchele (59), Dr. Katharina Kraft (36), Prof. Dr. Helga Rübsamen-Schaeff (70), Dr. Daniel Thelen (44) and Dr. Simon Thelen (39), they form the Board of Partners.

Prof. Dr. Gregor Schulz (68) and Prof. Dr. Theo Siegert (71) are no longer members.

For more information, please contact Constantin Birnstiel
+49 6151 72-56567
Email

About E. Merck KG

The general partner E. Merck KG (EM) holds 70.3% of the total capital of Merck KGaA; shareholders hold the remainder, which is divided into shares.

EM makes the fundamental entrepreneurial decisions of the Merck Group but it does not participate in the management of the company. The Merck family currently holds 99.9% of the capital of EM; the remaining interests are held by the members of the Executive Board of Merck KGaA.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Record changed: 2023-06-05